

# Trajan Scientific and Medical

Global Corporate Headquarters 7 Argent Place, Ringwood Victoria 3134, Australia Tel: +61 (0) 3 9837 4200 www.trajanscimed.com

Trajan Group Holdings Limited ACN 152 617 706

#### **ASX RELEASE**

## **FY21 APPENDIX 4E**

**25 August 2021 –** In accordance with ASX Listing Rules, please see attached Trajan Group Holdings Limited's (**ASX:TRJ**)(**Trajan** or **the Company**) Appendix 4E for the year ended 30 June 2021.

The associated year-end reporting documents will be provided separately as follows:

- Trajan FY21 Annual Report
- FY21 Corporate Governance Statement and Appendix 4G
- Trajan FY21 Results Release
- Trajan FY21 Investor Presentation

## **Investor Webcast**

Trajan will be holding a live webcast and Q&A hosted by Trajan CEO and Managing Director, Stephen Tomisich and Chief Financial Officer, Alister Hodges at 11:00am (AEST) today, 25 August 2021

To register for the webcast, please follow this link: <a href="https://trajanscimed.zoom.us/webinar/register/WN\_n-gTHA9aRoCroslEPfG7ww">https://trajanscimed.zoom.us/webinar/register/WN\_n-gTHA9aRoCroslEPfG7ww</a>

## 2021 Annual General Meeting

In accordance with ASX Listing Rule 3.13.1, Trajan advises that the 2021 Annual General Meeting of shareholders will be held on Wednesday, 24 November 2021. Further details regarding the 2021 Annual General Meeting including the Notice of Meeting will be made available to shareholders in accordance with regulatory requirements. Pursuant to ASX Listing Rule 14.3, valid nominations for the position of director are required to be lodged at the registered office of the Company by 5:00pm (AEST) on 6 October 2021.

Authorised for release by the Board of Trajan Group Holdings Limited.

**END** 

Contact:

Investors
Rebecca Wilson
WE Communications
investorrelations@trajanscimed.com

Media
Evonne Grosso
WE Communications
egrosso@we-worldwide.com



## **About**

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of 450 people, with five manufacturing sites across the US, Australia, and Malaysia, and operations in Australia, the US, Asia, and Europe.

# Trajan Group Holdings Limited Appendix 4E Preliminary final report

## 1. Company details

Name of entity: Trajan Group Holdings Limited

ABN: 38 152 617 706

Reporting period: For the year ended 30 June 2021 Previous period: For the year ended 30 June 2020

#### 2. Results for announcement to the market

	2021	2020	%
	\$'000	\$'000	
Revenue from ordinary activities	76,568	71,852	7%
Profit after income tax	1,880	2,608	(28%)
Profit attributable to ordinary equity holders	1,650	2,057	(20%)

Dividends

	Amount \$	Franking credit \$
Interim dividend for the year ended 30 June 2021 – declared and paid in May 2021	1,000,000	428,571
Final dividend for the year ended 30 June 2021 – declared and paid in June 2021	2,350,000	1,007,144

#### Comments

Please refer to Directors Report – Principal activities and Review of Operations in the attached Financial statements.

## 3. Statement of Profit or Loss and Other Comprehensive Income

Please refer to Statement of Profit or Loss and Other Comprehensive Income in the attached Financial statements.

## 4. Statement of Financial Position

Please refer to Statement of Financial Position in the attached Financial statements.

# 5. Statement of Cash Flows

Please refer to Statement of Cash Flows in the attached Financial statements.

## 6. Statement of Changes in Equity

Please refer to Statement of Changes in Equity in the attached Financial statements.

## 7. Dividend or Distribution reinvestment plans

There are no dividend or distribution reinvestment plans in operation.

# 8. Net tangible assets

	Reporting period \$	Previous period \$
Net tangible assets per ordinary security	0.50	1,414,583.33

## 9. Control gained over entities

Name of entities (or group of entities)
Date control gained

Trajan Nutrition Pty Ltd 1 July 2020

#### 10. Loss of control over entities

There are no entities over which control has been lost during the period.

## 11. Details of associates and joint venture entities

There are no associates or joint venture entities.

# 12. Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position

Please refer to section 2

# 13. Foreign entity accounting standards

Australian Accounting Standards and International Financial Reporting Standards

## 14. Commentary on result for the period

#### The earnings per security and the nature of any dilution aspects

Please refer to Note 22 in the financial statements

## Returns to shareholders including distributions and buy backs

Please refer to Note 19 in the financial statements

## Significant features of operating performance

Please refer to Directors Report – Principal activities and Review of Operations in the attached Financial statements.

## The results of segments that are significant to an understanding of the business

Please refer to Note 3 in the financial statements

## Discussion of trends in performance

Please refer to Directors Report – Principal activities and Review of Operations in the attached Financial statements.

## 15. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

## 16. Attachments

Details of attachments (if any):

The Annual Report of Trajan Group Holdings Limited for the year ended 30 June 2021 is attached